Analyzing the Future of Liver Diseases Therapeutics Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the liver diseases therapeutics market?
The market size for treatments of liver diseases has seen a substantial growth in past years, expanding from $14.16 billion in 2024 and projected to reach $15.23 billion by 2025 with a compound annual growth rate (CAGR) of 7.6%. Contributing factors to this growth in the historic period include the widespread incidence of liver diseases, patterns of alcohol consumption, advancements in diagnostic technology, obesity and metabolic syndrome, awareness and screening initiatives, alongside government-led efforts to control hepatitis.
What will be the liver diseases therapeutics market size in the future?
The market size for therapeutics in liver diseases is predicted to witness robust growth in the coming years, ballooning to $20.78 billion in 2029 with a compound annual growth rate (CAGR) of 8.1%. This predicted growth within the forecast period can be credited to the application of precision medicine, advancements in RNA therapeutics, emphasis on treatments for fibrosis, patient advocacy and supporting groups, hepatitis vaccines development, and regulatory backup for orphan drugs. The major trends predicted to influence this market during the forecast period include progress in hepatitis C treatment, the rise of new therapies for liver fibrosis, investigation of immunotherapies, the integration of telemedicine and distant monitoring, along with a concentration on nutritional interventions.
Get your liver diseases therapeutics market report here!
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
What main drivers are fueling expansion in the liver diseases therapeutics market?
The increasing occurrence of liver-related illnesses is poised to drive expansion in the liver disease therapeutics market. Essentially, liver disease suggests any issue impacting the liver, and the therapeutics aimed at liver disease include various types of treatment. For instance, data from the Office for Health Improvement and Disparities, a government department in the UK, indicated that in 2022, the death rate from liver disease among those under 75 in England increased to 21.4 per 100,000 inhabitants. This included 6,664 premature deaths in men as opposed to 3,929 in women. Consequently, this uptick in liver disease occurrence is a key factor propelling the growth of the liver disease therapeutics market.
What key areas define the segmentation of the global liver diseases therapeutics market?
The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp
Who are the dominant players expanding their reach in the liver diseases therapeutics market?
Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
How are evolving market trends shaping liver diseases therapeutics Strategies?
The trend of forming strategic partnerships is rapidly increasing in popularity within the liver disease therapeutics market. Major firms in this market are establishing collaborations to solidify their market positions. A typical example was in January 2022 when Aligos Therapeutics Inc., a US clinical-stage biopharmaceutical company, forged a partnership with Merck & Co, a US firm also operating in the liver disease therapeutics market. The motive of the partnership is to uncover and develop oligonucleotide therapies for non-alcoholic steatohepatitis.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7969
Which regions are emerging as leaders in the liver diseases therapeutics market?
North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Digital Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report
Neurodegenerative Disorder Therapeutics Global Market Report 2024
Peptide Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
